Blood products

Largest US blood services organization; supplies 40% of US whole blood and blood components (red blood cells, platelets, plasma) from volunteer-only donations; does not perform commercial plasma fractionation; declared severe shortage after 35% supply drop in January 2026

Largest plasma fractionator globally; ~33% market share; operates the world's single largest fractionation facility (Broadmeadows, Australia, processing 10M+ liters/year); subsidiary of CSL Limited (ASX: CSL); acquired Vifor Pharma 2022

German multinational producing the Hi-Flow Plus nitrocellulose membrane — one of the two industry-standard LFA membranes globally. Received a €121M US DoD/HHS contract to build the first US lateral flow membrane facility in Sheboygan, WI (2022) to reduce concentration risk in Cork, Ireland.

Vitalant (Scottsdale AZ; nonprofit 501(c)(3); formed by merger of Blood Systems, United Blood Services, and BloodSource in 2017-2019; ~$800M revenue) is the largest nonprofit blood bank in the US by number of donation centers — operating 120+ donation centers and serving 850+ hospitals across 28 states. Vitalant collects approximately 30% of US whole blood supply. Vitalant's geographic strength is the US Mountain West, Southwest, and Pacific Northwest — regions served by relatively few large blood centers. Vitalant's formation through the merger of multiple regional blood banks was driven by economies of scale in blood processing, testing, and distribution. Vitalant introduced blood delivery by drone (Zipline partnership) for remote hospital delivery in Rwanda before US regulatory approval.

Croda International plc (Goole, East Riding of Yorkshire, UK; LSE: CRDA; ~£1.7B revenue) is a specialty chemicals company producing high-performance ingredients for consumer care, life sciences, and industrial applications. Croda's industrial chemicals division produces fatty acid derivatives and specialty esters relevant to fuel additive formulation chemistry — including dimer acid derivatives that overlap with the chemistry platform of jet fuel corrosion inhibitors. Croda's Goole, Yorkshire facility is its historic UK manufacturing base. Croda is primarily an indirect player in aviation CI chemistry — supplying raw material chemistry platforms rather than finished aviation-specification CI products — but its dimer acid and fatty acid derivative expertise is relevant to the corrosion inhibitor supply chain.

Second-largest plasma company globally; operates 400+ plasma collection centers worldwide; processes ~25% of global plasma supply; investing EUR 160M in Barcelona fractionation expansion (2025); major US presence through Talecris acquisition

World's largest vaccine manufacturer by dose volume — ~1.9–2.0 billion doses/year as of 2023, representing ~60% of global vaccine production. Produces routine childhood vaccines (polio, measles, DTP, BCG), COVID vaccines, and others for Gavi-eligible markets. Single-site concentration risk in Pune.

Major Indian antivenom maker; supplies Asian and African markets.

Takeda Pharmaceutical Company Limited (Tokyo Japan; TSE: 4502; NYSE: TAK; ~¥4.3T revenue; Japan's largest pharmaceutical company) is the world's #3 plasma fractionator through its Plasma-Derived Therapeutics (PDT) business division — the operations acquired from Baxter International's BioScience division in 2014 (BaxAlt / Baxalta acquisition completed 2016 for $32B). Takeda's PDT segment produces IVIG (GAMMAGARD LIQUID, HYQVIA), albumin, Factor VIII/IX/VWF products, and alpha-1 antitrypsin (GLASSIA) for immunodeficiency, hemophilia, hereditary angioedema, and respiratory disease patients globally. Takeda operates plasma collection centers under the BioLife Plasma Services brand in the US (300+ centers) and fractionation facilities in Lessines Belgium, Los Angeles CA, Covington GA, and Atlanta GA. Takeda's 2016 $32B acquisition of Shire (including Shire's Baxalta plasma business) was the largest acquisition in Japanese corporate history at the time.

Third-largest plasma fractionator (~29.5% market share); built through acquisitions of Shire (2019, $62B) and Baxalta; major hemophilia and immunology plasma portfolio; PDT (plasma-derived therapies) division is a standalone business unit

World's largest chemical company by revenue; dominant Western producer of food-grade sodium nitrite. BASF expanded sodium nitrite production capacity in Germany specifically to meet growing demand for high-purity pharmaceutical and food applications. Primary production at Ludwigshafen (world's largest contiguous chemical complex). Also produces sodium nitrite catalysts, sulfuric acid, and intermediates for pharmaceutical synthesis. BASF sells food-grade sodium nitrite to meat processors globally through distribution networks and third-party channels.

Specialty chemicals major; significant Western producer of phosphorus trichloride (PCl3) and other phosphorus-based chemicals.

New York Blood Center Enterprises (New York NY; nonprofit; formed 2019 by merger of NYBC + New England region blood centers + Southeast region; ~$700M revenue) is one of the largest US blood bank organizations — supplying blood to 200+ hospitals in New York, New Jersey, New England, and Southeast states. NYBC operates the New York City metropolitan area blood supply — one of the most complex transfusion medicine markets in the world. NYBC's research division has done foundational work in blood storage duration and transfusion outcomes. NYBC holds the blood supply contracts for Memorial Sloan Kettering, NYU Langone, and most major NYC hospital systems. In 2024, NYBC faced controversy when its lease for a Harlem community blood center — historically serving Black blood donors critical for sickle cell disease patients — was ended; advocates argued this reduced access to race-matched donors for sickle cell community.

Octapharma AG (Lachen, Schwyz Switzerland; private; founded 1983 by Wolfgang Marguerre who remains owner; ~€3.5B revenue) is the world's largest privately-owned plasma fractionator — and the largest plasma company not listed on a stock exchange. Octapharma produces IVIG (Octagam, Gammaplex), albumin (Albiomin), Factor VIII/IX (Nuwiq, Wilate), and clotting factors from plasma collected at its 250+ OctaPlasma collection centers in the US and Europe. Octapharma's willingness to remain private gives it long-term investment horizons that publicly-traded competitors face pressure against. Octapharma operates fractionation facilities in Vienna Austria, Springe Germany, Stockholm Sweden, Copenhagen Denmark, and Lingolsheim France. Founded by a single Austrian pharmacist, Octapharma has grown to become a major global pharmaceutical company through retained earnings rather than capital markets.

Self-described 'leading global player in the harvesting, processing and distribution of natural casings, meat products and pharmaceutical products.' Part of SARIA's Food & Pharma division since 2017; SARIA is also parent of Devro (collagen casings) — making SARIA the parent of the world's largest natural casing company AND the world's largest collagen casing company simultaneously. Van Hessen operates gutrooms inside slaughterhouses globally, positioned 'close to the source.' Also extracts pharmaceutical raw materials (heparin, collagen) from the same intestines processed for casings. Recent acquisitions: full ownership of Westpol-Teeuwissen (Netherlands/Poland).

Fourth-largest plasma fractionator globally (~10-12% market share); privately owned; operates 190+ plasma donation centers and multiple fractionation plants; major supplier of IVIG, albumin, and von Willebrand factor to European and US markets

One of China's major commercial-scale natural casing processors; located in Rugao, Jiangsu province. Rugao is historically one of China's leading natural casing processing centers — a concentration of casing businesses that has grown up around the hog slaughter industry in Jiangsu. Representative of the Chinese processing cluster that handles ~70% of global natural casing volume. Chinese processors import raw casings (pre-cleaned gut) from source countries, process and salt them, and export finished casings globally. COVID lockdowns 2020-2022 disrupted Rugao and similar Chinese casing processing hubs.

Primary US crude heparin processor; purifies Chinese and other crude porcine heparin into active pharmaceutical ingredient (API). SPL's Chinese supplier (Changzhou SPL, Jiangsu) was identified as the source of the contaminated crude heparin that caused ~81 deaths in 2008. Despite the crisis, SPL remains a major US heparin API processor -- there are very few alternatives at scale. SPL now operates under enhanced FDA oversight and Chinese facility inspection protocols.